Neuropace Inc

NPCE remains in a Stage 2 advancing uptrend supported by rising EMAs, but the active Blow-Off Top pattern signals a climax of buying pressure and waning momentum. Short-term price is pulling back into the rising 9/21 EMA support zone on early RSI rollover, making immediate entry unfavorable. We will wait for a cleaner pullback into these dynamic support levels before engaging bullishly.

• ↑Q1 2026 revenue $22.1M (+8% YoY); full-year guide raised to $99–101M.
• ↑RNS system gross margin strong at 82.5% supports unit economics.
• ↓Q1 net loss $6.7M and adjusted EBITDA loss $3.3M highlight cash burn.